Business
Karyopharm Announces Changes to Its Clinical Leadership Team
− Patricia Judson, M.D., Formerly of GSK and AstraZeneca, Appointed as Senior Vice President of Medical Strategy - − Stuart Poulton, Formerly of AbbVie,
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"− Patricia Judson, M.D., Formerly of GSK and AstraZeneca, Appointed as Senior Vice President of Medical Strategy -\n − Stuart Poulton, Formerly of AbbVie, Amgen, and Eli Lilly, Joins as Senior Vice President of Strategy and Portfolio Management -\n − Jatin Shah, M.D., Stepping Down as Executive Vice President, Chief Medical Officer -\n\n\nNEWTON, Mass., Feb. 22, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management. In addition, Jatin Shah, M.D. Executive Vice President and Chief Medical Officer has stepped down to pursue other professional opportunities, but will continue to serve Karyopharm in an advisory capacity.\n\"As accomplished leaders with proven track records, Patricia and Stuart's expertise will be instrumental as we work to progress our pipeline in our four core program areas, with the goal of bringing innovative new treatments to patients with high unmet need,\" said Richard Paulson, President and Chief Executive Officer of Karyopharm. \"I'd also like to take this opportunity to sincerely thank Jatin for his important contributions over the past five years and wish him the best in his next endeavor.\"\nDr. Judson brings more than 25 years of oncology experience to her new role. Prior to joining Karyopharm, she served as Vice President and Global Head of Women's Oncology, Medical Affairs at GSK. Previously, Dr. Judson served as the U.S. Medical Head for the DNA Damage Response Franchise in Women's Oncology at AstraZeneca. She began her career as an academic gynecologic oncologist and is a peer-recognized scientist with experience in translational cancer research, as well as clinical trial design and management. Dr. Judson completed her M.D. at the University of Minnesota School of Medicine, Residency in Obstetrics & Gynecology at the University of California, San Francisco, and her Fellowship in Gynecologic Oncology at the University of North Carolina at Chapel Hill.\nMr. Poulton has more than 25 years of experience in the global biotech and pharmaceutical space. He joins Karyopharm from AbbVie, wher...